Ask AI
Multidisciplinary Management of CML

CE / CME

Community Practice Grand Rounds: Practical Guidance for Optimal Multidisciplinary Management of Chronic Myeloid Leukemia

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Pharmacists: 0.75 contact hour (0.075 CEUs)

Nurse Practitioners/Nurses: 0.75 Nursing contact hour, including 0.75 hour of pharmacotherapy credit

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Released: July 28, 2025

Expiration: January 27, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following would cause you to investigate a potential therapy change for a patient who has been receiving imatinib 400 mg daily with no tolerability issues?

2.

Patient Case



  • 52-yr-old male with history of HTN, COPD, and CAD s/p CABG 2 yr ago presents with fatigue, night sweats, and increasing abdominal fullness

  • Physical exam reveals splenomegaly

  • CBC reveals WBC 212,000/μL, HCT 38%, and PLTS 515,000/μL

  • High Sokal score

  • Bone marrow biopsy is hypercellular with 3% blasts

  • Cytogenetic analysis reveals t(9;22), and PCR shows BCR::ABL1 transcript (p210) at value of 92% IS

In your clinical practice, which of the following targeted therapies would you consider most appropriate for this patient?

3.

Which of the following patient conditions meets criteria for considering TKI discontinuation and attempting TFR?

4.

Patient Case



  • 55-yr-old female who is a former smoker (10 pack-yr history, quit  1 yr ago) with CAD and recent MI, is diagnosed with CP-CML and started on bosutinib 

  • BCR::ABL1 after 12 months: 0.18%

  • BCR::ABL1 after 18 months: 3%

  • No drug–drug interactions are present, and she reports good adherence to all medications, including bosutinib

  • Subsequent mutation analysis reveals T315I mutation

Which of the following is the most appropriate therapy for this patient?